- Success of Nasdaq IPO in February 2021
- €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023
- Strong growth of operational expenses to €26.8M, mainly reflecting clinical program advancement in COVID-19 (COVA) and in sarcopenia (SARA)
- Significant milestones reached for COVA and SARA allowing to prepare for future development of the programs
Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
